Patents Assigned to Argenta Discovery Ltd.
-
Publication number: 20110319446Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; wherein A is an oxygen atom or group —N(R12)—; (i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group —R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2 is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to whiType: ApplicationFiled: June 20, 2011Publication date: December 29, 2011Applicant: Argenta Discovery Ltd.Inventors: Harry Finch, Nicholas Charles Ray, Richard James Bull, Monique Bodil van Niel, Andrew Stephen Robert Jennings
-
Publication number: 20110046191Abstract: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a ?2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.Type: ApplicationFiled: February 6, 2008Publication date: February 24, 2011Applicants: ARGENTA DISCOVERY LTD., ASTRAZENECA ABInventors: Finch Harry, Wiley Katherine, Dixon JOhn
-
Patent number: 7846955Abstract: The invention provides [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-yl-methyl]-dimethyl-ammonium napadisylate, pharmaceutical compositions containing it, and its use in therapy.Type: GrantFiled: February 6, 2008Date of Patent: December 7, 2010Assignees: AstraZeneca AB, Argenta Discovery Ltd.Inventors: Barbara Giuseppina Avitabile, David O'Sullivan, Richard James Bull
-
Publication number: 20100093816Abstract: The invention provides [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-yl-methyl]-dimethyl-ammonium napadisylate, pharmaceutical compositions containing it, and its use in therapy.Type: ApplicationFiled: February 6, 2008Publication date: April 15, 2010Applicants: ARGENTA DISCOVERY LTD., ASTRAZENECA ABInventors: Barbara Giuseppina Avitabile, David O'Sullivan, James Richard Bull
-
Publication number: 20090182033Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; formula (I) wherein R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group -R5 or a group, -Z-Y—R5, or a group -Z-NR9R10, or a group -Z-N(R9)C(O)R11; and R3 is a lone pair, or C1-C6-alkyl; R4 is selected from one of the groups of formula (a), (b), (c) or (d); formulae (a), (b), (c), (d), Z is a C1-C16-alkylene, C2-C16-alkenylene or C2-C16-alkynylene group; Y is a bond or oxygen atom; R5 is an C1-C6-alkyl, aryl, arylalkyl; aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C1-C8-alkyl)-, heteroaryl(C1-C8-alkyl)-, cycloalkyl or heterocycloalkyl group; R6 is C1-C6-alkyl or a hydrogen atom; R7a and R7b area C1-C6-alkyl group or halogen; n and m are independently 0, 1, 2 or 3; R8a and R8b are independently selected from the group consisting of aryl, aryl-fused-heterocycloalkyl, heteroaryl, C1-C6-alkyl, cycloalkyl and hydrogen; R8c is —OH, C1-C6-alkyl, hydroxy-C1-C6-alkyl, or a hydrogen atom; R8d is C1-C6Type: ApplicationFiled: December 14, 2006Publication date: July 16, 2009Applicant: ARGENTA DISCOVERY LTD.Inventors: Harry Finch, Nicholas Charles Ray, Monique Bodil Van Niel, Phillip Smith
-
Publication number: 20080269239Abstract: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.Type: ApplicationFiled: November 11, 2005Publication date: October 30, 2008Applicant: Argenta Discovery Ltd.Inventors: Neil Harris, Christopher Higgs, Stephen Wren, Hazel Dyke, Steven Price, Sue Cramp